"Belt and Road Initiative" National Drug Supervision and Development Cooperation Seminar and "Belt and Road Initiative" National Pharmaceutical Supervision Cooperation and Industrial Development Seminar
Release time:
2021-09-07
On September 1, 2021, the opening ceremony of the "Belt and Road" National Drug Regulatory and Development Cooperation Seminar and the "Belt and Road" National Pharmaceutical Regulatory Cooperation and Industrial Development Seminar co-sponsored by the State Food and Drug Administration and the Ministry of Commerce was held online and offline in Beijing.
Xu Jinghe, deputy director of the State Food and Drug Administration, attended the meeting and delivered a speech. Officials and experts from health and drug regulatory agencies from 17 countries, including Armenia, Egypt, Ghana, Kenya, Lebanon, Lesotho, Liberia, Mozambique, Mongolia, Pakistan, Sri Lanka, Senegal, Tanzania, Uganda, Ukraine, Uzbekistan and Zambia, attended the seminar.
Xu Jinghe pointed out that promoting medical and health cooperation and building a healthy Silk Road is an important part of jointly building "Belt and Road Initiative," which provides a broad space for bilateral and multilateral cooperation and market development in the field of medicine and health. at the same time, it also brings more opportunities for drug regulatory exchanges and cooperation among countries along the route. In the face of the sudden outbreak of new coronary pneumonia, the Chinese government and the international community have jointly promoted the construction of a global immunization defense line, making China's contribution to the accessibility and affordability of vaccines in developing countries. The State Food and Drug Administration of China has made every effort to promote the approval of emergency medical equipment to ensure that vaccine drugs and medical devices needed for epidemic prevention and control are put into use as quickly as possible to effectively serve epidemic prevention and control. At the same time, the State Food and Drug Administration of China has continued to deepen the reform of the review and approval system, a series of laws and regulations to encourage the innovation of drugs and medical devices have been introduced one after another, and the pace of listing innovative drugs and medical devices has been further accelerated, contributing Chinese wisdom and strength to the construction of a human health community.
Xu Jinghe stressed that drug safety is a major issue of global concern. Addressing drug safety requires the full cooperation of the international community. In the era of globalization and information, it is particularly necessary to strengthen the cooperation and exchange of drug supervision among "Belt and Road Initiative" countries. It is hoped that the seminar will continue to deepen exchanges and cooperation in the field of drug supervision in countries along the "Belt and Road Initiative" route, and promote the stable improvement of the overall level of drug supervision. At the same time, we should give full play to the role of bridges and bonds, promote traditional friendship and cooperative relations among countries along the "Belt and Road Initiative" route, and jointly make new and greater contributions to the protection and promotion of human health.
At the meeting, participants held a thematic discussion on "Belt and Road Initiative" national drug supervision and development cooperation. Gao Li, the representative of the World Health Organization in China, introduced global public health cooperation during the new crown pandemic. A number of representatives of the seminar introduced their country's pharmaceutical regulatory system and the development of the pharmaceutical industry, and exchanged their experience in the prevention and control of the new crown epidemic and international cooperation. Representatives from the State Food and Drug Administration, the Ministry of Science and Technology, the Ministry of Industry and Information Technology, and the China Center for Disease Control and Control also made speeches.
The 14-day seminar will adopt a combination of online and offline methods. Through cloud lectures, cloud seminars, cloud visits, cloud inspections and other live webcasts, all students will understand the situation of China's drug supervision and communicate with representatives of the Chinese pharmaceutical industry. Various discussion forms enhance the participation and sense of acquisition of students to promote drug regulatory exchanges between China and the "Belt and Road" countries and promote cooperation in the pharmaceutical industry.
Source: National Drug Administration
Recommend Content
Share
Contact Information
Telephone:+86 0377-6169 3188
E-mail:office@sislan.cn
Address: South End of Beijing Avenue, Nanyang City, Henan Province
Copyright© SISLAN (Nanyang) Pharmaceutical Co., Ltd.
SAF Coolest v1.3.1.2 设置面板 XSYSD-ZEHE-FXSVE-EWS
无数据提示
Sorry, the current column is being updated, please look forward to it!
You can view other columns or returnHome Page